15 Posts Not to Miss from the 3rd Day of ASCO 2025
@ascocancer.bsky.social
@drnataliagandur.bsky.social
@bookiephronesis.bsky.social
@icr.ac.uk
@viveksubbiah.bsky.social
oncodaily.com/societies/as...
#ASCO2025 #ATOMICtrial #Cancer #MATTERHORNtrial #OncoDaily #Oncology #SERENA6 #Veritac2
@ascocancer.bsky.social
@drnataliagandur.bsky.social
@bookiephronesis.bsky.social
@icr.ac.uk
@viveksubbiah.bsky.social
oncodaily.com/societies/as...
#ASCO2025 #ATOMICtrial #Cancer #MATTERHORNtrial #OncoDaily #Oncology #SERENA6 #Veritac2
15 Posts Not to Miss from the 3rd Day of ASCO 2025 - OncoDaily
15 Posts Not to Miss from the 3rd Day of ASCO 2025 / American Society of Clinical Oncology, Armando Orlandi, ASCO, ASCO 2025, ASCO 25, ATOMIC trial, cancer,
oncodaily.com
June 4, 2025 at 10:26 AM
15 Posts Not to Miss from the 3rd Day of ASCO 2025
@ascocancer.bsky.social
@drnataliagandur.bsky.social
@bookiephronesis.bsky.social
@icr.ac.uk
@viveksubbiah.bsky.social
oncodaily.com/societies/as...
#ASCO2025 #ATOMICtrial #Cancer #MATTERHORNtrial #OncoDaily #Oncology #SERENA6 #Veritac2
@ascocancer.bsky.social
@drnataliagandur.bsky.social
@bookiephronesis.bsky.social
@icr.ac.uk
@viveksubbiah.bsky.social
oncodaily.com/societies/as...
#ASCO2025 #ATOMICtrial #Cancer #MATTERHORNtrial #OncoDaily #Oncology #SERENA6 #Veritac2
MATTERHORN Trial at ASCO 2025: Durvalumab plus FLOT Shows Significant Improvement of EFS in Resectable Gastric and GEJ Cancer Treatment
@ascocancer.bsky.social
oncodaily.com/oncolibrary/...
#ASCO #ASCO2025 #CancerResearch #Duvralumab #GastricCancer #MATTERHORNtrial #OncoDaily #Oncology
@ascocancer.bsky.social
oncodaily.com/oncolibrary/...
#ASCO #ASCO2025 #CancerResearch #Duvralumab #GastricCancer #MATTERHORNtrial #OncoDaily #Oncology
MATTERHORN Trial at ASCO 2025: Durvalumab plus FLOT Shows Significant Improvement of EFS in Resectable Gastric and GEJ Cancer Treatment - OncoDaily
MATTERHORN trial at ASCO 2025: Durvalumab + FLOT improves event-free survival in resectable gastric cancer, signaling a new standard of care.
oncodaily.com
June 1, 2025 at 9:15 PM
MATTERHORN Trial at ASCO 2025: Durvalumab plus FLOT Shows Significant Improvement of EFS in Resectable Gastric and GEJ Cancer Treatment
@ascocancer.bsky.social
oncodaily.com/oncolibrary/...
#ASCO #ASCO2025 #CancerResearch #Duvralumab #GastricCancer #MATTERHORNtrial #OncoDaily #Oncology
@ascocancer.bsky.social
oncodaily.com/oncolibrary/...
#ASCO #ASCO2025 #CancerResearch #Duvralumab #GastricCancer #MATTERHORNtrial #OncoDaily #Oncology
What if immunotherapy could help cure certain GI cancers? The #MATTERHORNtrial is testing this—adding durvalumab before & after surgery more than doubled the number of patients with no visible cancer. FDA fast-track could be next. #ASCO25
🔗: https://meetings.asco.org/abstracts-presentations/245972
🔗: https://meetings.asco.org/abstracts-presentations/245972
May 29, 2025 at 7:08 PM
What if immunotherapy could help cure certain GI cancers? The #MATTERHORNtrial is testing this—adding durvalumab before & after surgery more than doubled the number of patients with no visible cancer. FDA fast-track could be next. #ASCO25
🔗: https://meetings.asco.org/abstracts-presentations/245972
🔗: https://meetings.asco.org/abstracts-presentations/245972
#NICE #NICErecommedation #NHS #HEOR #AstraZeneca #Imfinzi #durvalumab #gastriccancer #Oncology #MSD #Winrevair #sotatercept #pulmonaryarterialhypertension #PAH #immunotherapy #PDL1inhibitor #GEJcancer #MATTERHORNtrial #StomachCancerUK #PAHtherapy #pulmonaryhypertension #PHAUK
zurl.co/iBqfl
zurl.co/iBqfl
NICE backs stomach cancer, PAH drugs for NHS use
AZ's Imfinzi is the first NHS immunotherapy for a form of stomach cancer, while MSD's Winrevair gets a green light for rare respiratory disease PAH.
pharmaphorum.com
May 19, 2026 at 2:13 PM